EPI-X4 is a peptide antagonist of CXCR4 with therapeutic prospects for cancer and inflammatory disorders.

Sagini MN, Berger MR, Muthmann J, Alt E, Forssmann WG.

DOI: 10.1016/j.peptides.2026.171479
Published: 2026-02-21
Container: Peptides
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.peptides.2026.171479,
  title = {EPI-X4 is a peptide antagonist of CXCR4 with therapeutic prospects for cancer and inflammatory disorders.},
  author = {Sagini MN and  Berger MR and  Muthmann J and  Alt E and  Forssmann WG.},
  year = {2026},
  journal = {Peptides},
  doi = {10.1016/j.peptides.2026.171479},
  url = {https://doi.org/10.1016/j.peptides.2026.171479}
}

RIS

TY  - JOUR
TI  - EPI-X4 is a peptide antagonist of CXCR4 with therapeutic prospects for cancer and inflammatory disorders.
AU  - Sagini MN
AU  -  Berger MR
AU  -  Muthmann J
AU  -  Alt E
AU  -  Forssmann WG.
PY  - 2026
JO  - Peptides
DO  - 10.1016/j.peptides.2026.171479
UR  - https://doi.org/10.1016/j.peptides.2026.171479
ER  -

APA

MN, S., MR, B., J, M., E, A., & WG., F. (2026). EPI-X4 is a peptide antagonist of CXCR4 with therapeutic prospects for cancer and inflammatory disorders.. Peptides. https://doi.org/10.1016/j.peptides.2026.171479

Source records

europe-pmc · retrieved 2026-09-27T02:48:31.048Z